Background. Neonatal invasive candidiasis (IC) presenting in the first week of life is less common and less well described than later-onset IC. Risk factors, clinical features, and disease outcomes have not been studied in early-onset disease (EOD, ≤7 days) or compared to late-onset disease (LOD, >7 days).
Invasive candidiasis (IC) in preterm infants is associated with serious morbidity and high mortality [1] . Within the spectrum of IC is a subset of infants with early onset of disease (EOD) [2, 3] . EOD is considered to be congenital in origin and a rare entity, although the incidence is unreported [1, 2, 4, 5] . Publications on EOD have been limited to case reports or series that mainly highlight the milder noninvasive cutaneous variant [4, [6] [7] [8] . Although accounts of the invasive form of disease with early onset are uncommon, they generally describe a fulminant course of systemic illness, particularly in extremely low birth weight (ELBW) infants (<1000 g) [8] [9] [10] [11] .
We sought to determine the incidence of the EOD variant of IC within a prospective cohort of ELBW infants with IC, to describe the demographic, clinical, and microbiological features of EOD compared to late-onset disease (LOD), and to determine whether EOD in ELBW infants was associated with a higher likelihood of an unfavorable outcome than LOD, as measured by mortality and/or neurodevelopmental impairment (NDI).
METHODS
The Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospectively collected data on all infants ≤90 days of age at infection onset presenting from 2001 to 2003 with IC (Candida species identified from blood, cerebrospinal fluid [CSF] , or other sterile body fluid [excluding urine], or histopathological, ophthalmologic, or autopsy evidence of IC) across 13 tertiary care neonatal intensive care units (NICUs). For the subset of cases occurring in infants of birth weight <1250 g, uninfected controls were enrolled (2:1) matched for age, sex, birth weight (±100 g), and gestational age (±6 days), to study neurodevelopmental outcomes in survivors who had been followed up to corrected ages of 1.5-2 years [12] .
For the analysis of congenital cases, we included all ELBW infants with IC and their matched controls. Cases were subclassified as (1) EOD: onset of IC within the first 7 days of life, to maintain consistency with previously published timelines for congenital candidiasis [2, 4, [7] [8] [9] [10] ; and (2) LOD: onset of IC after 7 days of life. Infants with isolated cutaneous congenital candidiasis were not included, as they did not fulfil enrollment criteria for IC. The day of onset was the day of collection of the first sterile site specimen from which a Candida species isolate was obtained, with the exception of cases of Candida species chorioamnionitis, for which onset date was the day of birth.
Definitions of disease are as follows:
• Central nervous system (CNS) candidiasis: positive CSF/ brain culture, or yeast on brain histopathology, or candidemia plus ≥1 of: CSF white blood cell count >25 × 10 6 /L in a nonbloody CSF, CSF protein ≥2.0 g/L, CSF:serum glucose ratio <0.5, or head ultrasound compatible with CNS candidiasis.
• Cardiovascular system candidiasis: candidemia with valvular or mural endocarditis, myocardial abscess, aneurysm, vasculitis, or thrombus.
• Candida chorioamnionitis: placenta culture or microscopy positive for Candida species.
• Candida pneumonia: Candida species isolated from pleural fluid or lung tissue. • Disseminated infection: positive Candida species culture, or end-organ disease on autopsy in ≥2 noncontiguous sterile body sites, or by ≥2 premortem assessments: ultrasound examination of heart and/or vessels, abdominal ultrasound, ophthalmological examination, lumbar puncture, or cranial imaging.
• NDI: presence of ≥1 of the following: blindness, deafness, moderate to severe cerebral palsy, or a score of <70 in the Mental Developmental Index or Psychomotor Developmental Index components of the Bayley Scales of Infant Development, second edition (BSID-II) [13] .
The study protocol was approved by the ethics review board at each hospital. The existing standard of care at each institution was not altered during the study. During the study period, routine fluconazole prophylaxis was not used in any of the participating centers. The primary outcome was mortality. Secondary outcomes included NDI and NDI combined with mortality.
Statistical Analysis
Univariate analyses of the dichotomous variables of interest including perinatal (composite factor that combined vaginal delivery and ≥1 perinatal risk factors, eg, chorioamnionitis, intrauterine device) and demographic factors as well as disease outcomes (disseminated disease, mortality, and NDI) were used to compare EOD to LOD, using χ 2 tests or Fisher exact test, where appropriate. Comparison of means or medians was done using independent t tests or nonparametric tests, where appropriate. Sample size was too small to allow multivariate conditional logistic regression. Survival curves were compared using log-rank tests. Mortality risk for each of the disease groups was compared to its respective matched control group using conditional logistic regression. Univariate logistic regression was applied to determine whether timing of IC onset predicted mortality. For the matched analysis using conditional logistic regression (1 case to 2 controls), the sample size available (14 pairs for EOD; 31 pairs for LOD) provided 80% power to detect a significant difference in proportion of 0.7-0.9 and 0.35-0.8 at the 95% confidence level for EOD and LOD, respectively, assuming a baseline proportion (mortality rate) of <0.15 [12] in the control population. Sample size was too small to allow unconditional logistic regression of other outcomes (disseminated infection or NDI). EpiInfo software version 7 (Centers for Disease Control and Prevention) was used for the statistical analysis. Female sex, birth weight <750 g, gestational age ≤24 weeks, vaginal delivery chorioamnionitis of any etiology and the combination of vaginal delivery plus ≥1 perinatal risk factor were all significantly (P < .05) associated with EOD compared to LOD (Table 1) . Infants with EOD were more likely to have been born vaginally to a mother with chorioamnionitis and/or intrauterine foreign body than were matched controls, whereas there was no significant difference in the occurrence of these factors between LOD cases and their matched controls. (Tables 2 and 3; Supplementary Table) CNS Six of 9 (67%) infants who had a lumbar puncture or autopsy evaluation for CNS candidiasis fulfilled the following criteria (Table 2) : positive CSF culture (n = 2) and pleocytosis or abnormal chemistry with a positive blood culture (n = 4). One of the latter had cranial ultrasound abnormalities.
RESULTS

Sixty
Descriptive Analysis of EOD
Lung
All of 12 infants assessed had evidence of pneumonia (Table 2,  Supplemental Table) coinciding with or following the onset of candidiasis, of which 5 were confirmed to be Candida pneumonia.
Cardiovascular System
Five of the 6 infants with cardiovascular disease had evidence of persistent candidemia (83%), with a median of 5 (range [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] positive blood cultures detected over a median of 10 days (range 4-28) from the first positive culture. The single case without persistent candidemia had only 1 blood culture taken before death. At autopsy, endocarditis was detected, in addition to numerous microabscesses and granulomata in the myocardium. One case had endocarditis and an atrial mural thrombus, while 4 others had intravascular thrombi (Supplemental Table) .
Renal
Three infants had ultrasound evidence of fungal balls in the collecting system and one had bilateral microabscesses in the renal parenchyma at autopsy, despite negative urine cultures at presentation (Supplemental Table) . A fifth presumed case had Candida tropicalis isolated from the urine and the blood, supporting a diagnosis of pyelonephritis, despite a negative ultrasound.
Gastrointestinal
One infant had hepatic candidiasis at autopsy (Table 2) . Premortem imaging had not been performed in this child and was negative in 7 other investigated infants. Four cases demonstrated other forms of gastrointestinal involvement: peritonitis (n = 2), bowel wall granulomata with abscesses at autopsy (n = 1), and a subphrenic fluid collection (n = 1) (Supplemental Table) .
Skin and Other
Six (43%) infants presented with skin manifestations (2 pustular lesions, 2 superficial erosions [excoriations], 2 generalized erythematous rash)( Table 2, Supplemental Table) . Half of these cases had chorioamnionitis. Deep skin invasion was documented in 2 cases at autopsy, only 1 of which had a documented rash. Endophthalmitis was not observed (Supplemental Table) .
Treatment
Twelve (86%) EOD infants were treated with antifungal agents (Table 3) : amphotericin B alone (7 [58%]) or amphotericin B and 5-fluorocytosine (5-FC) combined (5 [42%] ). Therapy was begun within 48 hours of diagnosis in 8 of 12 (67%) infants, and 1 each at 3, 4, 5, and 9 days. Among the 4 cases with treatment onset delayed ≥3 days, all had histological evidence of Candida species chorioamnionitis that was not reported to Cervical suture (n = 1) or intrauterine device (n = 4). Intrauterine foreign bodies were present in 6% of controls and their presence was a factor that was significantly different across EOD, LOD, and controls (P = .03). c Perinatal risk factors included chorioamnionitis and intrauterine foreign body. Maternal antibiotic use and prolonged rupture of membranes were not analyzed as sufficient data were not available. . Three (50%) of those with skin rash in EOD had mothers with chorioamnionitis, whereas none of those with skin rash in LOD had mothers with chorioamnionitis (P = .055).
*P < .05.
the responsible physician until after positive placental culture results were available. The 2 fatal untreated cases died before laboratory confirmation of IC became available.
Outcome (Table 3) 10 of 14 (71%) EOD infants died of any cause, with 90% of deaths determined to be Candida related (Candida-specific rate, 9 of 14 [64%]). Mortality was high in the 13 EOD infants with disseminated disease (9/13 [69%]). One case with incomplete assessment for disseminated disease died. Two of the 4 survivors had normal examinations, while the other 2 (50%) had NDI. Overall, 12 (86%) infants with EOD died or had NDI. Autopsies were performed at a similar rate in EOD (40%) and LOD cases (30%).
EOD Versus LOD
Microbiology
Candida albicans caused significantly more EOD than LOD (P < .02) ( Table 1) .
Clinical
The spectrum of organ disease was not significantly different between EOD and LOD, except for pneumonia (P = .016), cardiovascular disease (P = .044), and disseminated disease (P = .003), which were more common in EOD ( 
Treatment
EOD and LOD survivors were treated for a median duration of 18.5 (range 14-67) days and 25 (range 13-84) days, respectively (Table 3) . No significant difference in treatment duration, type of antifungal, or use of combination therapy was observed.
Primary Outcome
Thirty-day mortality was significantly higher in EOD than LOD cases (64% vs 26%; P = .021; Table 3 ). In the matched conditional analysis that controlled for sex, gestational age and birth weight, IC predicted mortality in EOD (P = .009) but not in LOD (P = .051). Survival curves were significantly different for cases and their matched controls for both EOD (P = .003) and LOD (P = .021) (Figures 1 and 2 ).
Secondary Outcomes
The rate of NDI was similar in EOD and LOD cases (Table 3) . When NDI was combined with death, there was a significant difference across the 3 groups (EOD, LOD, and controls) (P = .007), although not between EOD and LOD cases (P = 1.00).
DISCUSSION
This is the first prospective study to compare clinical, treatment, and outcome differences in "congenital systemic candidiasis" (or EOD) to LOD and to uninfected matched controls. Our study provides evidence that IC causes severe and frequently fatal disease in ELBW infants with EOD. The all-cause Rate of NDI or mortality in controls was 44% and significantly different compared with EOD and LOD (P = .007).
and the Candida-related mortality rates associated with EOD are approximately twice as high as in infants with LOD. In the matched analysis, which controlled for gestational age, birth weight, and sex, infants with EOD were noted to be 3 times more likely to die than were their matched controls (P = .009); the study was, however, underpowered to detect mortality risk in the matched analysis for the LOD cohort although it almost reached significance (P = .051). Outcome following EOD is dismal, with a combined mortality and NDI rate of 86%, compared with 72% in LOD cases. The combined mortality/NDI rate in EOD is largely influenced by mortality. It is also probable that the very high rate of dissemination in EOD (93%) compared with LOD (42%) contributed to the higher mortality in EOD. The incidence of EOD was high in our prospective cohort of ELBW infants with IC (31%). Other studies have not provided comparable data for disease occurring within 7 days of life.
Clinically, the spectrum of organ involvement differed in EOD compared with LOD infants. Serious cardiovascular complications were more common in EOD (75%) than LOD (30%), and cutaneous manifestations, described in the literature as usually associated with a more benign course, were present in 43% of EOD cases compared with 26% of LOD cases at presentation. Furthermore, >80% of EOD infants with rash, including pustular, erosive, and erythematous variants, developed disseminated disease. Skin rash also appears to be a potential risk factor for predicting EOD, especially in the context of maternal chorioamnionitis, as our study showed a trend toward significance (P = .055).
Both pneumonia and histological chorioamnionitis were strongly associated with EOD, and support the pathogenetic role of prenatal infection of the fetoplacental unit and/or aspiration of infected vaginal secretions during birth [14] . Our analysis supports the perinatal mode of transmission in that both vaginal delivery and chorioamnionitis were risk factors for EOD. The presence of a maternal intrauterine device (IUD) has been reported to be associated with cases of congenital candidiasis [8] , though we could not show significance in EOD vs LOD. There was, however, a significant difference across EOD, LOD, and controls (P = .03), suggesting that a larger sample size would be helpful. We have also shown that it is the most preterm infants (birth weight <750 g or gestational age <25 weeks) that carry the highest risk of EOD. Together, these findings suggest that a high index of suspicion for IC should be entertained in the extremely preterm infant with pneumonia and any type of skin rash, who is delivered vaginally, and in whom perinatal maternal risk factors are present such as histological or clinical chorioamnionitis or an indwelling IUD. Other independent risk factors for IC in LBW infants should also be considered in assessing probability of disease, such as cephalosporin/ broad-spectrum antibiotic use, lack of enteral feeding, presence of an endotracheal tube or central intravenous catheter, receipt of intravenous lipid emulsion, thrombocytopenia, necrotizing enterocolitis, and intrapartum antibiotics [1, 12, 15, 16] .
Published reports of cases of IC presenting within the first few days of life have documented Candida species infection of the placenta, cord, or amniotic fluid [11, [17] [18] [19] , as we did in 5 of the 14 EOD cases. In addition, reports of placental or endometrial candidiasis that culminate in stillbirth or spontaneous abortion indicate that in utero infection can result in death [19] [20] [21] [22] . The importance of the early recognition of histopathological and microbiological findings of candidiasis in the placenta is demonstrated by 2 cases (1 fatal) in our study. Positive cultures for Candida species from placentas showing chorioamnionitis were not reported to the attending physician until 8 days of life, despite results being available earlier. Findings of candidiasis in the placenta should be reported promptly to the infant health record, thus permitting earlier diagnosis and treatment.
Candida albicans was significantly more likely to cause EOD (79%) than LOD (39%) in our study, whereas Candida parapsilosis was a more prominent cause of LOD (39%) than of EOD (14%). These findings are consistent with acquisition of C. albicans from the maternal vagina in EOD [23] , whereas C. parapsilosis is more commonly associated with factors linked to postnatal acquisition, such as total parenteral nutrition, central venous catheters, and contaminated medical equipment or solutions [24, 25] .
The median duration of treatment in surviving EOD cases in our study was 18.5 days, which is notably shorter than the minimum duration of 3 weeks recommended by the Infectious Diseases Society of America (IDSA) for treatment of neonatal candidiasis [26] . LOD cases were treated for a median of 7 days longer, which, although not statistically significant, conforms to IDSA guidelines and might have influenced outcome and mortality.
A limitation of our study was that incomplete perinatal data collection prevented exploration of some other perinatal factors that may also be important. In addition, the high case fatality rate resulted in too few surviving infants to study risk factors for long-term neurodevelopmental morbidity, such as dissemination, CNS infection, and infective endocarditis. A larger sample size would have allowed more extensive subgroup analyses.
A strength of our study is that it preceded the era of routine fluconazole prophylaxis, and thus was a clean comparison of disease outcome between EOD and LOD infants, naive to any antifungal intervention until diagnosis. Although fluconazole prophylaxis has been clearly demonstrated to reduce the incidence of invasive disease in preterm infants [27] and has been recommended for use in infants with birth weight <1000 g in NICUs with high rates of candidiasis (≥15%) [26] , its uptake as a routine preventive strategy has been limited in the United States, Europe [28, 29] , and Canada, where none of the participating centers in this study used it during or after the study. Although low burden of disease in Canadian NICUs and concerns regarding safety and resistance were the main reasons, this stance has been further supported by the recent observation that fluconazole prophylaxis did not result in a lower combined incidence of death or IC in infants weighing <750 g [30] . This may be due to the inclusion of IC cases associated with chorioamnionitis and EOD cases presenting between 3 and 7 days of life, which may have masked a mortality benefit of prophylaxis [28, 31] . Future prophylaxis studies should ensure that cases of perinatal onset are excluded from the IC case group, given that EOD causes high mortality and is not likely to be impacted by such a strategy.
This study is the first to provide data on early-onset or perinatal IC from a prospective observational study, and to compare EOD and LOD in ELBW infants. EOD occurring as a consequence of intrauterine or intrapartum acquisition of infection is a distinct entity associated with a higher mortality rate than that observed in LOD. Given that empiric antifungal therapy has been shown to improve survival and reduce NDI outcomes in IC [31] , it seems prudent to recommend consideration of this intervention in suspected EOD where prophylactic strategies are not likely to reduce incidence. Other potential strategies include antenatal identification of mothers at risk of delivering infants with EOD so that maternal therapeutic or preventive antifungal interventions can be entertained. Clinicians should maintain a high index of suspicion for the EOD variant of IC as the cause of early-onset neonatal sepsis in high-risk infantsthat is, ELBW infants delivered vaginally with pneumonia and skin rash, whose mothers had an IUD or clinical/histological chorioamnionitis, in addition to other previously identified risk factors for IC in LBW infants. Our data highlight this group of infants as a select group that may benefit from prompt empiric therapy.
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